Increased gray matter volume in lithium-treated bipolar disorder patients
Section snippets
Acknowledgments
This study was supported by NIMH grants MH01736, MH29618, and MH30915, the Theodore and Vada Stanley Foundation, NARSAD, and CAPES Foundation (Brazil).
References (7)
- et al.
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness
Biol. Psychiatry
(2000) - et al.
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects?
Biol. Psychiatry
(2000) - et al.
Lithium-induced increase in human brain grey matter
Lancet
(2000)
There are more references available in the full text version of this article.
Cited by (219)
Elevated choline in dorsolateral prefrontal cortex of lithium responders with bipolar I disorder
2023, Asian Journal of PsychiatryBipolar disorder and plasticity: A key target for new treatment
2022, Biomarkers in Bipolar DisordersPosttranslational modifications & lithium's therapeutic effect—Potential biomarkers for clinical responses in psychiatric & neurodegenerative disorders
2021, Neuroscience and Biobehavioral ReviewsThe relationship between maintenance and manipulation components of working memory and prefrontal and parietal brain regions in bipolar disorder
2020, Journal of Affective DisordersCitation Excerpt :As most studies of bipolar disorder, many of our bipolar patients were medicated, namely on lithium. Previous studies have shown that lithium is associated with increased gray matter volumes in bipolar patients (Bearden et al., 2007; Sassi et al., 2002). Therefore, the absence of group differences in gray matter volume may have been a reflection of medication.
Copyright © 2002 Elsevier Science Ireland Ltd. All rights reserved.